🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Closer towards a donor for everyone! Fantastic working with this team Brian Shaffer Antonio Jimenez Jimenez Steven Devine Jeff Auletta Monzr M. AlMalki, MD Steve Spellman

This is extremely important work supported by NMDP and CIBMTR. Use of MMUD with PTCy truly means there are donors for all! | PTCy–Based GVHD Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors ascopubs.org/doi/10.1200/JC…

Wow! This is incredible work that can really open up during our transplantation to many more patients. What a remarkable study!

Hahaha! This is what my better half is doing while I twiddle my thumbs in clinic ☺️

In Journal of Clinical Oncology, Dana-Farber CIBMTR researchers found that using post-transplant cyclophosphamide results in comparable outcomes between HLA-matched & mismatched unrelated donor hematopoietic cell transplants, expanding access for patients of all ancestries. ascopubs.org/doi/10.1200/JC…

Journal of Clinical Oncology Brian Shaffer Important paper from CIBMTR and NMDP demonstrating the evolving potential for PTCy to expand access to HCT for all patients regardless of ancestry

Wonderful sharing the stage with these rising stars! Antonio Jimenez Jimenez Ioannis Politikos

🚨Breaking News/Good News from #ASH24🚨 >90% 1-year OS in PTCy-treated alloHCT recipients age 70+ enrolled in BMT CTN 1703! 😱 Important analysis by Sameem Abedin Mehdi Hamadani, MD Javier Bolaños Meade, MD and team!! 🙌 ash.confex.com/ash/2024/webpr… #PTCyrules

#BMTCTN1703 #PTCyRules

Amazing to have been part of this endeavour! #donorsforeveryone Steven Devine Brian Shaffer Antonio Jimenez Jimenez Monzr M. AlMalki, MD Jeff Auletta Steve Spellman

An instant classic!! Executed by some of the smartest people I know :D Shernan Holtan MD Javier Bolaños Meade, MD Mehdi Hamadani, MD @DrMiguelPerales Brian Shaffer

🚨 New findings from the BMT CTN 1703 trial: Post-transplant cyclophosphamide (PTCy) lowers patient-reported #GVHD symptom burden vs Tac/MTX in the first year after transplant. 📊🩺 #PTCyRules Congrats, team!! 💪 Javier Bolaños Meade, MD Mehdi Hamadani, MD ascopubs.org/doi/10.1200/JC…

Great experience collaborating with Moses for this review!! Star mentees make our jobs easy :) H. Moses Murdock

An excellent and practical review! Bravo H. Moses Murdock Dana-Farber News #AMLsm

Asciminib plus dasatinib and prednisone for Philadelphia chromosome–positive acute leukemia ashpublications.org/blood/article-… by Dr. Luskin et al. #leusm #ALL 100% CR. At day 84, 100% of patients achieved complete cytogenetic remission. At day 84, 74% and 26% achieved BCR::ABL1

Contributions that cannot be quantified..one of the true pioneering giants in transplantation !! Congratulations Joe Antin :). Corey Cutler Dana-Farber News

Congratulations to Dana-Farber researcher Joseph H. Antin, MD, who received the ASTCT Lifetime Achievement Award during #Tandem25. He was honored for his ongoing contributions to cellular therapy by advancing scientific knowledge in the field.

Congratulations to Joseph Antin, MD, recipient of the ASTCT Lifetime Achievement Award. This recognition is given to a physician who has made continuing contributions to the BMT and cellular therapy fields through the advancement of knowledge through basic or clinical science.

India’s first indigenous CAR-T therapy is now peer-reviewed in The Lancet Haematology , showing a 73% response rate—marking a breakthrough in accessible, cutting-edge cancer treatment.

How I treat AML relapse after allogeneic HSCT ashpublications.org/blood/article-… #AML #leusm